India's Cipla Not Ready For U.S. Biosimilars Market Even As Peers Line Up For Bigger Piece Of Pie
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Cipla - India's largest drug maker by market share - will not be amongst the first bunch of companies that prepare to launch biosimilars in the U.S
You may also be interested in...
On The Cusp Of Biosimilars: Reform Ushers In Next Generic Drug Era
The health care reform legislation signed into law by President Obama March 23 paves the way for the launch of biosimilar drugs in the U.S., action that could save the country's health care system billions of dollars, while presenting both challenges and opportunities for the drug industry
Indian Court Says "No" To Linking Patents With Regulatory Approvals; Sends Back Six Patent Oppositions
MUMBAI - In two back-to-back judgments delivered by the Delhi High Court this week, multinational drug companies Bayer and Eli Lilly suffered major setbacks as the Indian court rejected their separate pleas - one related to the linkage of patent grants with regulatory approvals and the other a re-examination of the existing system for patent oppositions
India's Dr. Reddy's Has All Guns Blazing On Biosimilars; Plans To Go After Top 10
HYDERABAD, India - Enthused by the success of its first monoclonal antibody Reditux - a copy of Genentech's Rituxan (rituximab) - India's Dr. Reddy's Labs is making a full throttle attempt to develop and launch copies of most blockbuster biotech drugs available in the international markets